Evidence map›Paper›PMID 33095413›Full record

ArticleInternal and emergency medicine2021

Can oral formulation increase the risk of lormetazepam abuse?

Enrico Costa, Enrico Sterzi, Federico Tedeschi, Rebecca Casari, Paola Marini, Fabio Lugoboni

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Zolpidem: A masked hero. A reply to ZORRO study.British journal of clinical pharmacology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Enrico CostaDepartment of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona,, P. le L.A. Scuro, 10, 37134, Verona, Italy. enrico.costa@aovr.veneto.it.
Enrico SterziDepartment of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona,, P. le L.A. Scuro, 10, 37134, Verona, Italy.
Federico TedeschiSection of Psychiatry and Clinical Psychology, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, Verona, Italy.
Rebecca CasariAddiction Medicine Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Paola MariniDepartment of Pharmacy, Azienda Ospedaliera Universitaria Integrata Verona,, P. le L.A. Scuro, 10, 37134, Verona, Italy.
Fabio LugoboniAddiction Medicine Unit, Department of Medicine, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.
Azienda Ospedaliera Universitaria Integrata Verona · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The slowness of dripping and the presence of alcohol have been offered/suggested as possible causes for the increased risk of developing dependence to the oral formulation of lormetazepam rather than to other anxiolytic and hypnotic drugs. We hence assessed the time of dripping of the most used benzodiazepines and z-drugs oral solution products under experimental conditions and the different employed excipients through a comparative analysis of the Summaries of Product Characteristics. A wide range of the median overall dispensing time was found across the eight products included in the analysis. Among the products containing LMZ, Minias

Indexed as

Administration, OralEthanolHumansHypnotics and SedativesLorazepamRisk FactorsSubstance-Related DisordersEthanolHypnotics and SedativesLorazepamlormetazepamDependency and toleranceLormetazepamOral liquid formulation

Identifiers

PMID33095413
OpenAlexW3093827811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.